



Omega Pharma acquires Persee Médica

- **First major activity related to the renewed *Star Category* strategy: enhancement of leading position in the wart treatment market**
- **Unique opportunity to roll out and internationalize three promising products already successful in France, including an anti-snoring product and a sleep regulation product**

Nazareth, Belgium 5 April 2007 — Omega Pharma has reached an agreement with the owners/founders of Persee Médica to acquire this French company. Omega Pharma will pay 20.2 million euro in cash to acquire 100 per cent of the Persee Médica shares.

With three staff members, three brands and four product references, Persee Médica generated a turnover of approximately 12 million euro in 2006. The brands and products of Persee Médica are perfectly suited for further internationalization beginning in 2008. As a consequence of this ‘add-on’ acquisition, Omega Pharma is adjusting its guidance for 2007 turnover ⁽¹⁾. The initial prognosis for the Consumer Health organization (between 820 and 840 million euro) is increased to 830 to 850 million euro. The 2007 turnover for the total group is consequently estimated between 1,130 and 1,150 million euro.

The representatives of the selling party, who will be responsible at Omega Corporate for the further internationalization of Persee Médica products, received counsel for this transaction from Aelios Finance, a French specialist in the field of Corporate Finance for growth-companies.

Omega Pharma will provide further details regarding this acquisition at a press and analyst meeting scheduled today at 15.00 CET in the company’s headquarters in Nazareth, Belgium. The presentation being made at this meeting will subsequently be available on the corporate Web site.

For more information, please contact:

Chris.Vanraemdonck@omega-pharma.be

0032/9/381.03.31 — 0032/499/58.55.31

⁽¹⁾ Disclaimer: This press release contains forward-looking information which is based on current internal estimates and expectations as well as market expectations. Forward-looking statements contain inherent risks and apply exclusively on the date they are made. The actual results may differ substantially from those included in the forward-looking statements.